Webdisclosure.com

Search

INVENTIVA (EPA:IVA) Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

Directive transparence : information réglementée

27/10/2021 22:00